Lancet Oncology: The light of hope for cancer patients, and the re-launch of universal targeted drugs can reduce the risk of disease progression and death by 78%!

Cabozantinib, a multi-target broad-spectrum anticancer drug, can inhibit multiple targets including MET, VEGFR2, RET, AXL, etc.
It has been used in kidney cancer, thyroid cancer, liver cancer, and soft tissue Sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer and other solid tumors have proven good therapeutic effects, especially for the control of bone metastasis.
Therefore, it is called "the golden oil in targeted drugs" ", "anti-cancer magic drug" and so on
.

Recently, the American pharmaceutical company Exelixis published the latest clinical trial progress on Cabozantinib in The Lancet Oncology for the treatment of differentiated thyroid cancer (DTC), with the title " Caboozantinib for radioiodine-refractory differentiated thyroid" cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial "
.

Clinical trial results show that cabozantinib can significantly prolong the progression-free survival of radioiodine-refractory DTC patients who have previously received VEGFR-targeted therapy, and can significantly reduce the risk of disease progression or death

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

https://doi.
org/10.
1016/S1470-2045(21)00332-6

https://doi.
org/10.
1016/S1470-2045(21)00332-6 https://doi.
org/10.
1016/S1470-2045(21)00332-6

Thyroid cancer has always been called "gentle cancer.
" Differentiated thyroid cancer accounts for 90-95% of thyroid cancer, mainly including papillary cancer and follicular cancer
.

Such cancer treatment strategies are flexible.

The clinical trial, named COSMIC-311, is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate the radioactivity of cabozantinib on previously received VEGFR targeted therapy Efficacy and safety of iodine-refractory DTC patients
.

187 patients from 164 clinics in 25 countries participated, randomly assigned to receive cabozantinib (n=125) or placebo (n=62) according to a 2:1 ratio.
Their median age was 66 years, 55% Of the patients are women who have been diagnosed with differentiated thyroid cancer and have been treated with sorafenib and levatinib before this trial
.

The objective response rate of 100 randomly assigned patients and the progression-free survival rate of all randomly assigned patients before the trial were the primary endpoints.
Among them, the objective response rate data was based on the objective response rate intention-to-treat population (OITT).
), and the progression-free survival rate is mainly in the intention-to-treat population (ITT).
Reaching any of the above endpoints indicates that the treatment of cabozantinib is better than placebo
.

Clinical trial data showed that in the interim analysis, the ITT population reached the primary endpoint of progression-free survival.
Compared with placebo, cabozantinib significantly reduced the risk of disease progression or death by 78%
.

In the ITT population, 76% of the patients who received cabozantinib had a target lesion reduction, while those who received a placebo had only 29% of the target lesion reduction; the two treatment groups did not achieve the median overall survival rate, but the Botinib still significantly improved the overall survival, the risk of death was significantly reduced by 46%, and its 6-month overall survival rate was even higher, reaching 85%

Comparison of the progression-free survival rate (A) and overall survival rate (B) between the cabozantinib group and the placebo group in the ITT population

Comparison of the progression-free survival rate (A) and overall survival rate (A) and overall survival rate (B) between the cabozantinib group and the placebo group in the ITT population The progression-free survival rate (A) and overall survival rate between the cabozinib group and the placebo group in the ITT population (B) Contrast

In terms of safety, the rate of discontinuation in the cabozantinib group due to adverse events caused by treatment was 5%, and 71 subjects had grade 3 or 4 adverse events.
The main symptoms were hand-foot syndrome, high blood pressure, fatigue and weakness
.

As early as February 2021, Cabozantinib has been granted breakthrough therapy designation by the US FDA for the treatment of radioactive iodine refractory differentiated thyroid cancer
.

Nowadays, the development of thyroid cancer is on the rise.

Original source:

Original source:

Marcia S Brose, et al.

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial in this message